{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:22:44Z","timestamp":1795090964018,"version":"4.10.2"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2020101"],"award-info":[{"award-number":["2020101"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-016"],"award-info":[{"award-number":["W81XWH-22-1-016"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0399"],"award-info":[{"award-number":["W81XWH-22-1-0399"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA279044"],"award-info":[{"award-number":["R01CA279044"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA286652"],"award-info":[{"award-number":["R01CA286652"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R21CA226082-01"],"award-info":[{"award-number":["1R21CA226082-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA260062"],"award-info":[{"award-number":["R37CA260062"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA279044"],"award-info":[{"award-number":["R01CA279044"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["71-22"],"award-info":[{"award-number":["71-22"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","award":["23IN37"],"award-info":[{"award-number":["23IN37"]}],"id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008126","name":"Dana-Farber\/Harvard Cancer Center","doi-asserted-by":"publisher","award":["2P50CA101942-16"],"award-info":[{"award-number":["2P50CA101942-16"]}],"id":[{"id":"10.13039\/100008126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008126","name":"Dana-Farber\/Harvard Cancer Center","doi-asserted-by":"publisher","award":["5P30CA006516-56"],"award-info":[{"award-number":["5P30CA006516-56"]}],"id":[{"id":"10.13039\/100008126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"DOI":"10.1038\/s42255-025-01218-9","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:03:13Z","timestamp":1738818193000},"page":"478-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-5877","authenticated-orcid":false,"given":"Jiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0552-209X","authenticated-orcid":false,"given":"Kaimeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananthan","family":"Sadagopan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin Nabil","family":"Laimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Mohanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary N.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-3368","authenticated-orcid":false,"given":"Mingkee","family":"Achom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingru","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwo-Shu Mary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9100-9638","authenticated-orcid":false,"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Lee","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine M.","family":"Cornejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta A.","family":"Ryback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2687-9546","authenticated-orcid":false,"given":"Liron","family":"Bar-Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-3023","authenticated-orcid":false,"given":"Srinivas R.","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"1218_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrurol.2014.162","volume":"11","author":"EC Kauffman","year":"2014","unstructured":"Kauffman, E. C. et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat. Rev. Urol. 11, 465\u2013475 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"1218_CR2","doi-asserted-by":"publisher","first-page":"110190","DOI":"10.1016\/j.celrep.2021.110190","volume":"38","author":"Z Bakouny","year":"2022","unstructured":"Bakouny, Z. et al. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 38, 110190 (2022).","journal-title":"Cell Rep."},{"key":"1218_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/cancers11081110","volume":"11","author":"A Cali\u00f2","year":"2019","unstructured":"Cali\u00f2, A., Segala, D., Munari, E., Brunelli, M. & Martignoni, G. MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge. Cancers 11, 1110 (2019).","journal-title":"Cancers"},{"key":"1218_CR4","doi-asserted-by":"publisher","first-page":"ra9","DOI":"10.1126\/scisignal.2004754","volume":"7","author":"JA Martina","year":"2014","unstructured":"Martina, J. A. et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci. Signal 7, ra9 (2014).","journal-title":"Sci. Signal"},{"key":"1218_CR5","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1158\/1078-0432.CCR-19-3283","volume":"26","author":"J Marcon","year":"2020","unstructured":"Marcon, J. et al. Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy-number variations as drivers of disease progression. Clin. Cancer Res. 26, 3629\u20133640 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1218_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25618-z","volume":"12","author":"G Sun","year":"2021","unstructured":"Sun, G. et al. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat. Commun. 12, 5262 (2021).","journal-title":"Nat. Commun."},{"key":"1218_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34460-w","volume":"13","author":"Y Qu","year":"2022","unstructured":"Qu, Y. et al. Proteogenomic characterization of MiT family translocation renal cell carcinoma. Nat. Commun. 13, 7494 (2022).","journal-title":"Nat. Commun."},{"key":"1218_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44159-1","volume":"14","author":"A Fukagawa","year":"2023","unstructured":"Fukagawa, A. et al. Genomic and epigenomic integrative subtypes of renal cell carcinoma in a Japanese cohort. Nat. Commun. 14, 8383 (2023).","journal-title":"Nat. Commun."},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","volume":"16","author":"WM Linehan","year":"2019","unstructured":"Linehan, W. M. & Ricketts, C. J. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat. Rev. Urol. 16, 539\u2013552 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"1218_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.2022.40.6_suppl.343","volume":"40","author":"O Alhalabi","year":"2022","unstructured":"Alhalabi, O. et al. Immuno-oncology (IO) combinations +\/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): results from an international multicenter study. JCO 40, 343\u2013343 (2022).","journal-title":"JCO"},{"key":"1218_CR11","doi-asserted-by":"publisher","unstructured":"Thouvenin, J. et al. Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas. Oncologist https:\/\/doi.org\/10.1093\/oncolo\/oyac158 (2022).","DOI":"10.1093\/oncolo\/oyac158"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1158\/1078-0432.CCR-18-0269","volume":"24","author":"NP Damayanti","year":"2018","unstructured":"Damayanti, N. P. et al. Therapeutic targeting of TFE3\/IRS-1\/PI3K\/mTOR axis in translocation renal cell carcinoma. Clin. Cancer Res. 24, 5977\u20135989 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1218_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6096-0","volume":"19","author":"EC Kauffman","year":"2019","unstructured":"Kauffman, E. C. et al. Preclinical efficacy of dual mTORC1\/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion. BMC Cancer 19, 917 (2019).","journal-title":"BMC Cancer"},{"key":"1218_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1158\/0008-5472.CAN-06-2855","volume":"67","author":"M Tsuda","year":"2007","unstructured":"Tsuda, M. et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 67, 919\u2013929 (2007).","journal-title":"Cancer Res."},{"key":"1218_CR15","doi-asserted-by":"publisher","first-page":"e17047","DOI":"10.7554\/eLife.17047","volume":"5","author":"A Calcagn\u00ec","year":"2016","unstructured":"Calcagn\u00ec, A. et al. Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling. eLife 5, e17047 (2016).","journal-title":"eLife"},{"key":"1218_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1158\/1541-7786.MCR-18-1235","volume":"17","author":"M Baba","year":"2019","unstructured":"Baba, M. et al. TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease. Mol. Cancer Res. 17, 1613\u20131626 (2019).","journal-title":"Mol. Cancer Res."},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/path.4158","volume":"229","author":"R Kobos","year":"2013","unstructured":"Kobos, R. et al. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein. J. Pathol. 229, 743\u2013754 (2013).","journal-title":"J. Pathol."},{"key":"1218_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2014.10.004","volume":"26","author":"N Riggi","year":"2014","unstructured":"Riggi, N. et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in ewing sarcoma. Cancer Cell 26, 668\u2013681 (2014).","journal-title":"Cancer Cell"},{"key":"1218_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","volume":"10","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V. & Cote, G. J. Advances in targeting RET-dependent cancers. Cancer Discov. 10, 498\u2013505 (2020).","journal-title":"Cancer Discov."},{"key":"1218_CR20","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","volume":"31","author":"J Laskin","year":"2020","unstructured":"Laskin, J. et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann. Oncol. 31, 1693\u20131703 (2020).","journal-title":"Ann. Oncol."},{"key":"1218_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer, R. J. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 38, 803\u2013817.e4 (2020).","journal-title":"Cancer Cell"},{"key":"1218_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313\u2013326.e5 (2018).","journal-title":"Cell Rep."},{"key":"1218_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110055","volume":"37","author":"R Elias","year":"2021","unstructured":"Elias, R. et al. A renal cell carcinoma tumorgraft platform to advance precision medicine. Cell Rep. 37, 110055 (2021).","journal-title":"Cell Rep"},{"key":"1218_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1586\/era.13.57","volume":"13","author":"B Shuch","year":"2013","unstructured":"Shuch, B., Linehan, W. M. & Srinivasan, R. Aerobic glycolysis: a novel target in kidney cancer. Exp. Rev. Anticancer Ther. 13, 711\u2013719 (2013).","journal-title":"Exp. Rev. Anticancer Ther."},{"key":"1218_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35833-5","volume":"14","author":"AH Nassar","year":"2023","unstructured":"Nassar, A. H. et al. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nat. Commun. 14, 346 (2023).","journal-title":"Nat. Commun."},{"key":"1218_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21707-1","volume":"12","author":"LK Gopi","year":"2021","unstructured":"Gopi, L. K. & Kidder, B. L. Integrative pan cancer analysis reveals epigenomic variation in cancer type and cell specific chromatin domains. Nat. Commun. 12, 1419 (2021).","journal-title":"Nat. Commun."},{"key":"1218_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"1218_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cmet.2023.01.012","volume":"35","author":"T Weiss-Sadan","year":"2023","unstructured":"Weiss-Sadan, T. et al. NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer. Cell Metab. 35, 487\u2013503.e7 (2023).","journal-title":"Cell Metab."},{"key":"1218_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215689","volume":"538","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma. Cancer Lett. 538, 215689 (2022).","journal-title":"Cancer Lett."},{"key":"1218_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cmet.2016.08.017","volume":"24","author":"JD Arroyo","year":"2016","unstructured":"Arroyo, J. D. et al. A genome-wide CRISPR death screen identifies genes essential for oxidative phosphorylation. Cell Metab. 24, 875\u2013885 (2016).","journal-title":"Cell Metab."},{"key":"1218_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/toxsci\/kfm052","volume":"97","author":"LD Marroquin","year":"2007","unstructured":"Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D. & Will, Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97, 539\u2013547 (2007).","journal-title":"Toxicol. Sci."},{"key":"1218_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","volume":"26","author":"CF Davis","year":"2014","unstructured":"Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319\u2013330 (2014).","journal-title":"Cancer Cell"},{"key":"1218_CR33","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1158\/0008-5472.CAN-20-0754","volume":"80","author":"Y Xiao","year":"2020","unstructured":"Xiao, Y. et al. Decreased mitochondrial DNA content drives OXPHOS dysregulation in chromophobe renal cell carcinoma. Cancer Res. 80, 3830\u20133840 (2020).","journal-title":"Cancer Res."},{"key":"1218_CR34","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","volume":"19","author":"WM Linehan","year":"2013","unstructured":"Linehan, W. M. & Rouault, T. A. Molecular pathways: fumarate hydratase-deficient kidney cancer\u2013targeting the Warburg effect in cancer. Clin. Cancer Res. 19, 3345\u20133352 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1218_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ccr.2011.07.018","volume":"20","author":"W-H Tong","year":"2011","unstructured":"Tong, W.-H. et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 20, 315\u2013327 (2011).","journal-title":"Cancer Cell"},{"key":"1218_CR36","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41586-024-07812-3","volume":"633","author":"D Bezwada","year":"2024","unstructured":"Bezwada, D. et al. Mitochondrial complex I promotes kidney cancer metastasis. Nature 633, 923\u2013931 (2024).","journal-title":"Nature"},{"key":"1218_CR37","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cmet.2018.07.020","volume":"28","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo. Cell Metab. 28, 793\u2013800.e2 (2018).","journal-title":"Cell Metab."},{"key":"1218_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/15548627.2017.1313943","volume":"14","author":"OA Brady","year":"2018","unstructured":"Brady, O. A., Martina, J. A. & Puertollano, R. Emerging roles for TFEB in the immune response and inflammation. Autophagy 14, 181\u2013189 (2018).","journal-title":"Autophagy"},{"key":"1218_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-cancerbio-030518-055835","volume":"3","author":"RM Perera","year":"2019","unstructured":"Perera, R. M., Di Malta, C. & Ballabio, A. MiT\/TFE family of transcription factors, lysosomes, and cancer. Annu. Rev. Cancer Biol. 3, 203\u2013222 (2019).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"1218_CR40","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41568-018-0054-z","volume":"18","author":"R Keshet","year":"2018","unstructured":"Keshet, R., Szlosarek, P., Carracedo, A. & Erez, A. Rewiring urea cycle metabolism in cancer to support anabolism. Nat. Rev. Cancer 18, 634\u2013645 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1218_CR41","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1016\/j.molcel.2021.08.005","volume":"81","author":"E Hajaj","year":"2021","unstructured":"Hajaj, E., Sciacovelli, M., Frezza, C. & Erez, A. The context-specific roles of urea cycle enzymes in tumorigenesis. Mol. Cell 81, 3749\u20133759 (2021).","journal-title":"Mol. Cell"},{"key":"1218_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40170-021-00271-8","volume":"9","author":"S Khare","year":"2021","unstructured":"Khare, S. et al. ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism. Cancer Metab. 9, 40 (2021).","journal-title":"Cancer Metab."},{"key":"1218_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.trecan.2023.10.002","volume":"10","author":"M Ge","year":"2024","unstructured":"Ge, M., Papagiannakopoulos, T. & Bar-Peled, L. Reductive stress in cancer: coming out of the shadows. Trends Cancer 10, 103\u2013112 (2024).","journal-title":"Trends Cancer"},{"key":"1218_CR44","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1089\/ars.2019.7803","volume":"32","author":"W Xiao","year":"2020","unstructured":"Xiao, W. & Loscalzo, J. Metabolic responses to reductive stress. Antioxidants Redox Signal. 32, 1330\u20131347 (2020).","journal-title":"Antioxidants Redox Signal."},{"key":"1218_CR45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1158\/2159-8290.CD-21-0922","volume":"12","author":"R Pillai","year":"2022","unstructured":"Pillai, R., Hayashi, M., Zavitsanou, A.-M. & Papagiannakopoulos, T. NRF2: KEAPing tumors protected. Cancer Discov. 12, 625\u2013643 (2022).","journal-title":"Cancer Discov."},{"key":"1218_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s43018-020-0071-1","volume":"1","author":"R Romero","year":"2020","unstructured":"Romero, R. et al. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nat. Cancer 1, 589\u2013602 (2020).","journal-title":"Nat. Cancer"},{"key":"1218_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.cmet.2015.04.009","volume":"21","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y. et al. SoNar, a highly responsive NAD+\/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell Metab. 21, 777\u2013789 (2015).","journal-title":"Cell Metab."},{"key":"1218_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1126\/science.aad4017","volume":"352","author":"DV Titov","year":"2016","unstructured":"Titov, D. V. et al. Complementation of mitochondrial electron transport chain by manipulation of the NAD+\/NADH ratio. Science 352, 231\u2013235 (2016).","journal-title":"Science"},{"key":"1218_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02540-7","volume":"22","author":"JM Dempster","year":"2021","unstructured":"Dempster, J. M. et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 22, 343 (2021).","journal-title":"Genome Biol"},{"key":"1218_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13805-y","volume":"10","author":"JM Dempster","year":"2019","unstructured":"Dempster, J. M. et al. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nat. Commun. 10, 5817 (2019).","journal-title":"Nat. Commun."},{"key":"1218_CR51","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1038\/s41388-020-1234-3","volume":"39","author":"MM Wolf","year":"2020","unstructured":"Wolf, M. M., Rathmell, W. K. & Beckermann, K. E. Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene 39, 3413\u20133426 (2020).","journal-title":"Oncogene"},{"key":"1218_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat. Med. 29, 115\u2013126 (2023).","journal-title":"Nat. Med."},{"key":"1218_CR53","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","volume":"162","author":"K Birsoy","year":"2015","unstructured":"Birsoy, K. et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162, 540\u2013551 (2015).","journal-title":"Cell"},{"key":"1218_CR54","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.molcel.2017.06.002","volume":"66","author":"M Ivan","year":"2017","unstructured":"Ivan, M. & Kaelin, W. G. The EGLN-HIF O2 -sensing system: multiple inputs and feedbacks. Mol. Cell 66, 772\u2013779 (2017).","journal-title":"Mol. Cell"},{"key":"1218_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","volume":"1","author":"C Shen","year":"2011","unstructured":"Shen, C. et al. Genetic and functional studies implicate HIF1\u03b1 as a 14q kidney cancer suppressor gene. Cancer Discov. 1, 222\u2013235 (2011).","journal-title":"Cancer Discov."},{"key":"1218_CR56","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1016\/j.cell.2024.07.038","volume":"0","author":"M Achom","year":"2024","unstructured":"Achom, M. et al. A genetic basis for sex differences in Xp11 translocation renal cell carcinoma. Cell 0, 5735\u20135752.e25 (2024).","journal-title":"Cell"},{"key":"1218_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","volume":"3","author":"J Kim","year":"2006","unstructured":"Kim, J., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177\u2013185 (2006).","journal-title":"Cell Metab."},{"key":"1218_CR58","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.celrep.2019.03.029","volume":"27","author":"J Miska","year":"2019","unstructured":"Miska, J. et al. HIF-1\u03b1 is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of tregs in glioblastoma. Cell Rep. 27, 226\u2013237.e4 (2019).","journal-title":"Cell Rep."},{"key":"1218_CR59","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen, N. et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N. Engl. J. Med. 381, 1001\u20131010 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1218_CR60","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1172\/JCI120855","volume":"129","author":"JC Chappell","year":"2019","unstructured":"Chappell, J. C., Payne, L. B. & Rathmell, W. K. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. J. Clin. Invest. 129, 442\u2013451 (2019).","journal-title":"J. Clin. Invest."},{"key":"1218_CR61","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-18-1354","volume":"9","author":"WM Linehan","year":"2019","unstructured":"Linehan, W. M. et al. The metabolic basis of kidney cancer. Cancer Discov. 9, 1006\u20131021 (2019).","journal-title":"Cancer Discov."},{"key":"1218_CR62","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41581-019-0210-z","volume":"16","author":"C Yong","year":"2020","unstructured":"Yong, C., Stewart, G. D. & Frezza, C. Oncometabolites in renal cancer: Warburg\u2019s hypothesis re-examined. Nat. Rev. Nephrol. 16, 156\u2013172 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1218_CR63","doi-asserted-by":"publisher","first-page":"E6283","DOI":"10.1073\/pnas.1711888115","volume":"115","author":"RK Gopal","year":"2018","unstructured":"Gopal, R. K. et al. Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. Proc. Natl Acad. Sci. USA 115, E6283\u2013E6290 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1218_CR64","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.clgc.2022.03.005","volume":"20","author":"X Yan","year":"2022","unstructured":"Yan, X. et al. Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma. Clin. Genitourin. Cancer 20, 354\u2013362 (2022).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1218_CR65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103240118","volume":"118","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proc. Natl Acad. Sci. USA 118, e2103240118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1218_CR66","doi-asserted-by":"publisher","first-page":"eadk8801","DOI":"10.1126\/sciadv.adk8801","volume":"10","author":"SD Shelton","year":"2024","unstructured":"Shelton, S. D. et al. Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis. Sci. Adv. 10, eadk8801 (2024).","journal-title":"Sci. Adv."},{"key":"1218_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.euros.2023.04.015","volume":"52","author":"SM Monda","year":"2023","unstructured":"Monda, S. M. et al. The metastatic risk of renal cell carcinoma by primary tumor size and subtype. Eur. Urol. Open Sci. 52, 137\u2013144 (2023).","journal-title":"Eur. Urol. Open Sci."},{"key":"1218_CR68","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1111\/j.1464-410X.2010.09818.x","volume":"108","author":"MC Mir","year":"2011","unstructured":"Mir, M. C. et al. Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. BJU Int. 108, E71\u20136 (2011).","journal-title":"BJU Int."},{"key":"1218_CR69","doi-asserted-by":"publisher","unstructured":"Sicinska, E. et al. ASPSCR1::TFE3 drives alveolar soft part sarcoma by inducing targetable transcriptional programs. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2115 (2024).","DOI":"10.1158\/0008-5472.CAN-23-2115"},{"key":"1218_CR70","doi-asserted-by":"publisher","first-page":"605","DOI":"10.15252\/emmm.201607204","volume":"9","author":"N Pastore","year":"2017","unstructured":"Pastore, N. et al. TFE3 regulates whole\u2010body energy metabolism in cooperation with TFEB. EMBO Mol. Med. 9, 605\u2013621 (2017).","journal-title":"EMBO Mol. Med."},{"key":"1218_CR71","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","volume":"164","author":"CT Hensley","year":"2016","unstructured":"Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164, 681\u2013694 (2016).","journal-title":"Cell"},{"key":"1218_CR72","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21, 297\u2013308 (2012).","journal-title":"Cancer Cell"},{"key":"1218_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"1218_CR74","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A. & Higgins, G. S. Oxidative phosphorylation as an emerging target in cancer therapy. Clin. Cancer Res. 24, 2482\u20132490 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1218_CR75","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/geroni\/igab046.1760","volume":"5","author":"N Chandel","year":"2021","unstructured":"Chandel, N. Metformin inhibits mitochondrial complex I to promote health. Innov. Aging 5, 454 (2021).","journal-title":"Innov. Aging"},{"key":"1218_CR76","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/0008-5472.CAN-18-2674","volume":"79","author":"C Price","year":"2019","unstructured":"Price, C. et al. Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers. Cancer Res. 79, 2564\u20132579 (2019).","journal-title":"Cancer Res."},{"key":"1218_CR77","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1038\/s41388-022-02378-8","volume":"41","author":"S Strocchi","year":"2022","unstructured":"Strocchi, S., Reggiani, F., Gobbi, G., Ciarrocchi, A. & Sancisi, V. The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation. Oncogene 41, 3665\u20133679 (2022).","journal-title":"Oncogene"},{"key":"1218_CR78","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.3390\/cancers12113458","volume":"12","author":"S Clerici","year":"2020","unstructured":"Clerici, S. & Boletta, A. Role of the KEAP1\u2013NRF2 axis in renal cell carcinoma. Cancers 12, 3458 (2020).","journal-title":"Cancers"},{"key":"1218_CR79","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccr.2013.10.025","volume":"24","author":"L Li","year":"2013","unstructured":"Li, L. et al. SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell 24, 738\u2013750 (2013).","journal-title":"Cancer Cell"},{"key":"1218_CR80","doi-asserted-by":"publisher","first-page":"e28083","DOI":"10.7554\/eLife.28083","volume":"6","author":"VI Sayin","year":"2017","unstructured":"Sayin, V. I. et al. Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. eLife 6, e28083 (2017).","journal-title":"eLife"},{"key":"1218_CR81","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41588-018-0155-3","volume":"50","author":"SR Viswanathan","year":"2018","unstructured":"Viswanathan, S. R. et al. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat. Genet. 50, 937\u2013943 (2018).","journal-title":"Nat. Genet."},{"key":"1218_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08949-w","volume":"10","author":"J Li","year":"2019","unstructured":"Li, J. et al. An alternative CTCF isoform antagonizes canonical CTCF occupancy and changes chromatin architecture to promote apoptosis. Nat. Commun. 10, 1535 (2019).","journal-title":"Nat. Commun."},{"key":"1218_CR83","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41592-020-01018-x","volume":"18","author":"C Stringer","year":"2021","unstructured":"Stringer, C., Wang, T., Michaelos, M. & Pachitariu, M. Cellpose: a generalist algorithm for cellular segmentation. Nat. Methods 18, 100\u2013106 (2021).","journal-title":"Nat. Methods"},{"key":"1218_CR84","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","volume":"22","author":"DR Stirling","year":"2021","unstructured":"Stirling, D. R. et al. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinform. 22, 433 (2021).","journal-title":"BMC Bioinform."},{"key":"1218_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson, K. R. et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).","journal-title":"Nat. Commun."},{"key":"1218_CR86","doi-asserted-by":"publisher","unstructured":"Li, B. et al. A framework for target discovery in rare cancers. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.10.24.620074 (2024).","DOI":"10.1101\/2024.10.24.620074"},{"key":"1218_CR87","doi-asserted-by":"publisher","first-page":"7074","DOI":"10.1021\/ac201267k","volume":"83","author":"T Fuhrer","year":"2011","unstructured":"Fuhrer, T., Heer, D., Begemann, B. & Zamboni, N. High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. Anal. Chem. 83, 7074\u20137080 (2011).","journal-title":"Anal. Chem."},{"key":"1218_CR88","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/jxb\/erac062","volume":"73","author":"S Koley","year":"2022","unstructured":"Koley, S., Chu, K. L., Gill, S. S. & Allen, D. K. An efficient LC-MS method for isomer separation and detection of sugars, phosphorylated sugars, and organic acids. J. Exp. Bot. 73, 2938\u20132952 (2022).","journal-title":"J. Exp. Bot."},{"key":"1218_CR89","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/bioinformatics\/btt080","volume":"29","author":"P Kiefer","year":"2013","unstructured":"Kiefer, P., Schmitt, U. & Vorholt, J. A. eMZed: an open source framework in Python for rapid and interactive development of LC\/MS data analysis workflows. Bioinformatics 29, 963\u2013964 (2013).","journal-title":"Bioinformatics"},{"key":"1218_CR90","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"1218_CR91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1218_CR92","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011).","journal-title":"BMC Bioinform."},{"key":"1218_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol"},{"key":"1218_CR94","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst"},{"key":"1218_CR95","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"1218_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"1218_CR97","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"1218_CR98","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"1218_CR99","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 128 (2013).","journal-title":"BMC Bioinform."},{"key":"1218_CR100","doi-asserted-by":"publisher","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ram\u00edrez","year":"2016","unstructured":"Ram\u00edrez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160\u2013W165 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1218_CR101","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"1218_CR102","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0895-822","volume":"1","author":"O Iliopoulos","year":"1995","unstructured":"Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1, 822\u2013826 (1995).","journal-title":"Nat. Med."}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01218-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01218-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01218-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:05:19Z","timestamp":1743311119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01218-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":102,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1038\/s42255-025-01218-9","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.V. has consulted for Jnana Therapeutics within the past 3 years and receives research support from Bayer. L.B.-P. is a co-founder, holds equity in and is a consultant for Scorpion Therapeutics. T.K.C. reports institutional and\/or personal paid and\/or unpaid support for research, advisory board, consultancy, and\/or honoraria past 5 years from Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Bicycle Therapeutics, Calithera, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GSK, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan\/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi\/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media Peerview, OncLive, MJH, CCO and others), outside the submitted work; institutional patents filed on molecular alterations and immunotherapy response\/toxicity, and ctDNA; equity from Tempest, Pionyr, Osel, PrecedeBio, CureResponse, InnDura Therapeutics, and Primium, Abalytics; is a committee member for NCCN, the GU Steering Committee, ASCO, ESMO, ACCRU, and KidneyCan; medical writing and editorial assistance support that might have been founded by communications companies in part, no speaker\u2019s bureau; mentored several non-US citizens on research projects with potential funding (in part) from non-US sources\/foreign components; the institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or\/and royalties potentially involved in research around the subject matter. S.S. reports receiving commercial research grants from Bristol Myers Squibb, AstraZeneca, Exelixis and Novartis; is a consultant\/advisory board member for Merck & Co., Rahway, NJ, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics AG, AACR and NCI; and receives royalties from Biogenex. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}